U.S. Employer And Workplace Drug Testing Market To Reach $4.01 Billion By 2033

U.S. Employer And Workplace Drug Testing Market Growth & Trends

The U.S. employer and workplace drug testing market size is expected to reach USD 4.01 billion by 2033, registering a CAGR of 5.2% from 2025 to 2033, according to a new report by Grand View Research, Inc. Regulatory compliance is a significant driver for market growth. Federal regulations, such as those from the Department of Transportation (DOT) and the Substance Abuse and Mental Health Services Administration (SAMHSA), mandate testing for safety-sensitive roles to ensure workplace safety and mitigate liability risks. These regulations enforce testing across industries, especially those involving heavy machinery or transportation.

In 2020, the American Public Health Association further emphasized the importance of drug testing by advocating for comprehensive strategies to address Opioid Use Disorder (OUD) and overdose risks in occupational settings. Their recommendations included strengthening injury prevention programs, addressing ergonomic risks, providing opioid misuse education, offering peer support, and regulating opioid prescriptions through workers' compensation. This policy push underscores the growing need for proactive drug testing measures.

In response to these regulatory and policy pressures, the U.S. DOT finalized new regulations in May 2023, allowing oral fluid testing for DOT-mandated drug tests, provided that at least two SAMHSA-certified laboratories are involved. This development highlights the evolving landscape of drug testing, enhancing the flexibility and accuracy of testing programs. By broadening testing options, the new regulation is expected to drive demand for oral fluid testing solutions, benefiting both employers and testing providers and supporting the overall market growth.

Additionally, the increase in substance use disorders (SUDs) among the workforce significantly impacts the growth of the U.S. employer & workplace drug testing market. The prevalence of these disorders contributes to higher rates of absenteeism, lower productivity, and increased workplace accidents. Employers are therefore compelled to implement rigorous drug testing programs to identify and address substance abuse issues promptly. This proactive approach not only helps in maintaining a safe and productive work environment but also reduces operational risks and legal liabilities associated with impaired employees. The growing recognition of the adverse effects of SUDs drives demand for more advanced and comprehensive drug testing solutions, contributing to the market’s expansion.

Furthermore, as organizations prioritize creating safer work environments, drug testing becomes an essential component of their safety programs. The awareness of the risks associated with substance abuse, including impaired judgment and increased accident rates, motivates employers to implement robust policies. This focus on safety is particularly pronounced in high-risk industries such as construction, manufacturing, and transportation. By identifying and addressing substance abuse issues, employers can mitigate potential hazards, improve overall workplace safety, and reduce associated costs. The increased awareness and commitment to safety drive the demand for comprehensive solutions, fueling market growth.

 Request a free sample copy or view report summary: U.S. Employer And Workplace Drug Testing Market Report

U.S. Employer And Workplace Drug Testing Market Report Highlights

• The post-employment segment dominated the market in terms of revenue share in 2024 and is expected to grow at a CAGR of 5.0% over the forecast period.  The pre-employment drug screens segment in the market is anticipated to grow at the fastest CAGR.

• The consumable segment dominated the market in terms of revenue share of 33.32% in 2024. The services segment is anticipated to grow at the highest CAGR from 2025 to 2033.

• The urine segment held the largest market share of 41.38% in 2024. The oral fluid segment is expected to grow at the fastest CAGR over the forecast period.

• The cannabis/marijuana segment held the largest market share of 57.32% in 2024 and is expected to grow at the fastest CAGR of 6.0% over the forecast period. The amphetamine & methamphetamine segment is expected to grow significantly in the forecast period.

• Other professional services dominated the market with the largest revenue share of 38.60% in 2024. Transportation is projected to experience significant growth over the forecast period, due to the critical importance of safety in this sector.

U.S. Employer And Workplace Drug Testing Market Segmentation

Grand View Research has segmented U.S. employer and workplace drug testing market on type, product, mode, drug and end-use:

U.S. Employer And Workplace Drug Testing Type Outlook (Revenue in USD Million, 2021 - 2033)

• Pre-employment Drug Screens

• Post-employment

U.S. Employer And Workplace Drug Testing Product Outlook (Revenue in USD Million, 2021 - 2033)

• Consumables

• Instruments

• Rapid Testing Devices

• Services

U.S. Employer And Workplace Drug Testing Mode Outlook (Revenue in USD Million, 2021 - 2033)

• Consumables

• Instruments

• Rapid Testing Devices

• Services

U.S. Employer And Workplace Drug Testing Drug Outlook (Revenue in USD Million, 2021 - 2033)

• Alcohol

• Cannabis/Marijuana

• Cocaine

• Opioids

• Amphetamine & Methamphetamine

• LSD

• Others

U.S. Employer And Workplace Drug Testing End-use Outlook (Revenue in USD Million, 2021 - 2033)

• IT/Finance

• Manufacturing

• Transportation

• Construction

• Retail and Hospitality

• Healthcare

• Education

• Other Professional Services

List of Key Players in the U.S. Employer And Workplace Drug Testing Market

• First Advantage

• Laboratory Corporation of America Holdings (Labcorp)

• Drägerwerk AG & Co. KGaA

• Bio-Rad Laboratories, Inc.

• Abbott

• Clinical Reference Laboratory Inc.

• Quest Diagnostics

• Cordant Health Solutions

• DISA Global Solutions

• HireRight, LLC

• OraSure Technologies, Inc.

• Omega Laboratories

• Psychemedics Corporation